PEL can arise very rarely de novo, while more frequently occurring as a therapy-related neoplasm or transformation from myelodysplastic syndromes (MDS).[4] This report presents a unique case of de novo PEL harboring EZH2 and TP53 frameshift mutations and rapid disease progression. Here, EZH2 is linked to myelodysplastic syndrome.